Abstract Details

Title Inflammation Biomarkers in Relation to Brain Amyloid Deposition in Non-Demented Older Adults

Topic Aging and Dementia

Presentation(s) S04 - (-)

Poster/Presentation
Number 004

Objective

Background Positron emission tomography imaging with amyloid specific ligands (e.g. PiB-PET) provide in vivo measurement of amyloid plaques in the brain. Inflammation and immune dysregulation are associated with dementia but their relation to amyloid deposition is not established.

Design/Methods Brain amyloid deposition was measured using PiB-PET on 178 participants aged 83-96 from the Gingko Evaluation of Memory (GEM) Study. Participants with adjudicated dementia (from neuropsychological testing) were excluded. Using stored plasma collected concurrent with the PiB testing, interleukin- 6 (IL-6), soluble IL-2 receptor (sIL-2r) and soluble CD-14 (sCD-14), were measured by ELISA (R&D Systems), soluble tumor necrosis factor- ? receptors 1 and 2 (sTNFr1/r2) by Multiplex Panel (Millipore), high-sensitivity C-reactive protein by nephelometry, and GlycA and GlycB, by NMR spectroscopy (LipoScience, Inc.).

Results More than half (99/179) of the non-demented older adults in this study had brain amyloid (i.e., using a SUVR cutoff >1.56 for PiB+). PiB+ participants had higher levels of GlycA and GlycB 607 vs. 570 and 215 vs. 192, p<0.05 for both), and also had higher levels of sTNFr2 and sCD14, but the differences did not reach statistical significance. Adjusted for age and sex, the odds of being PiB+ were 1.42(1.03, 1.95) and 1.43(1.04, 1.97) for a 1-SD increase in GlycA and GlycB, respectively.

Conclusions This is the first report of a possible association between novel NMR-determined biomarkers of inflammation/glycosylation, GlycA and GlycB, with brain amyloid in non-demented individuals. These results support a role for inflammation and immune function in brain amyloid deposition. Replication and further evaluation of the pathogenesis underlying this association is needed.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
William E. Klunk, MD, PhD (Western Psychiatric Institute and Clinic)	No disclosure on file
Russell Tracy	No disclosure on file
Chester Mathis (University of Pittsburgh Medical Center)	No disclosure on file
Steven T. DeKosky, MD, FAAN (McKnight Brain Institute)	Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acumen. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. DeKosky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail Pharamceuticls. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Vaccinex, Inc. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up-To-Date. Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics .
Thyagarajan Subramanian, MD, MBBS, FAAN (University of Toledo)	Dr. Subramanian has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Subramanian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus. Dr. Subramanian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Subramanian has received research support from National Institutes of Health. The institution of Dr. Subramanian has received research support from Ann and Phillip Gladfetler III Foundation. The institution of Dr. Subramanian has received research support from Department of Defense . Dr. Subramanian has received publishing royalties from a publication relating to health care. Dr. Subramanian has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with National Institutes of Health.
Oscar L. Lopez, MD, FAAN	Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acumen.

��ɫ��

��ɫ��